Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98.
Greer, Joel W
Date of Pub
Eggers, Paul W; Milam, Roger A
In this article the authors present descriptive data showing trends in human recombinant erythropoietin (EPO) doses, charges,
and patient hematocrits from the fourth quarter of calendar year 1989 to the first quarter of 1998 for all recipients and
recent data for patients treated by in-center hemodialysis. In 1997 nearly all in-center hemodialysis patients received EPO
regularly at an average cost per recipient of $6,245 per year for total allowed charges of $842.2 million per year. The study
shows that policy changes may have both anticipated and unanticipated effects on medical practice.
Drug Utilization Review : Anemia/drug therapy/etiology : Erythropoietin, Recombinant/administration & dosage/economics : Hemodialysis
Units, Hospital/economics : Human : Insurance, Health, Reimbursement/statistics & numerical data : Insurance, Pharmaceutical
Services/statistics & numerical data : Kidney Failure, Chronic/therapy : Medicare/statistics & numerical data : Treatment
Outcome : United States : United States Health Care Financing Administration